Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kelly Bedlan

Nurse Practitioner, Family Fort Myers, FL Nurse Practitioner

NPI 1841928801 CMS profile 11357410

12670 Creekside Ln Ste 202, Fort Myers, FL 33919

Open in the dashboard

General payments

$6,344

189 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Bedlan of Fort Myers, FL is reported in the CMS Open Payments database as having received $6,344 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,807 56
2024 General $1,975 55
2023 General $2,189 65
2022 General $373 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Bedlan
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kelly Bedlan were reported at $1,807. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kelly Bedlan Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $373 $141 $44–$430 $149
2023 $2,189 $154 $49–$476 $160
2024 $1,975 $165 $51–$504 $164
2025 $1,807 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,887 83 payments
  2. Boston Scientific Corporation $1,363 18 payments
  3. Medtronic, Inc. $520 12 payments
  4. Relievant Medsystems, Inc. $357 5 payments
  5. Collegium Pharmaceutical, Inc. $355 15 payments
  6. Pfizer Inc. $198 11 payments
  7. Globus Medical, Inc. $195 2 payments
  8. Lundbeck LLC $186 5 payments
  9. Nevro Corp. $178 7 payments
  10. Vertos Medical, Inc. $155 3 payments
  11. Other $950 28 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,909 187 payments
  2. Travel and Lodging $435 2 payments
Products named General payments · program years 2022–2025
  1. BOTOX Botox Therapeutic $769 37 payments
  2. UBRELVY $734 39 payments
  3. QULIPTA $599 24 payments
  4. Intracept Pain $379 6 payments
  5. Intracept Pain $357 5 payments
  6. Intracept Pain $357 5 payments
  7. Intracept Pain $357 5 payments
  8. BELBUCA $355 15 payments
  9. BOTOX Neuroscience $343 9 payments
  10. INTELLIS ADAPTIVESTIM $320 11 payments
  11. Other $2,675 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,377

Median for Nurse Practitioner: 389

Drug cost

$14,122

Median for Nurse Practitioner: $21,885

Branded share of claims

8.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 386 $3,958
Pregabalin Generic 153 $2,403
Baclofen Generic 117 $1,407
Cyclobenzaprine Hcl Generic 122 $1,215
Tramadol Hcl Generic 204 $1,190
Diclofenac Sodium Generic 20 $774
Calcitonin-Salmon Calcitonin,salmon,synthetic Brand 13 $662
Methocarbamol Generic 32 $645
Tizanidine Hcl Generic 64 $643
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 28 $351

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$118,733

Of which drugs: $6,483

Medicare patients

425

Average age 75

Services billed

3,853

235 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Depression 31%
Osteoporosis 29%
Diabetes 25%
Chronic kidney disease 23%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 102 933 $663

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $409
$409 — —
UBRELVY
  • AbbVie, Inc. $147
$147 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $98
$98 — —
QULIPTA
  • AbbVie, Inc. $96
$96 — —
NURTEC ODT
  • PFIZER INC. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record